Compounds > canertinib dihydrochloride
Page last updated: 2024-09-04

canertinib dihydrochloride and gefitinib

canertinib dihydrochloride has been researched along with gefitinib in 3 studies

Compound Research Comparison

Studies
(canertinib dihydrochloride)		Trials
(canertinib dihydrochloride)		Recent Studies (post-2010)
(canertinib dihydrochloride)		Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010) (gefitinib)
311365,2315662,919

Protein Interaction Comparison

ProteinTaxonomycanertinib dihydrochloride (IC50)gefitinib (IC50)
epidermal growth factor receptor isoform a precursorHomo sapiens (human)0.004
Cyclin-G-associated kinaseHomo sapiens (human)0.42
Multidrug resistance-associated protein 4Homo sapiens (human)4.6
Tyrosine-protein kinase ABL1Homo sapiens (human)1.2
Epidermal growth factor receptorHomo sapiens (human)0.3676
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.5699
Cytochrome P450 1A2Homo sapiens (human)0.151
Cytochrome P450 2E1Homo sapiens (human)0.46
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.7
Tyrosine-protein kinase HCKHomo sapiens (human)0.11
Quinolone resistance protein NorAStaphylococcus aureus9.7
Cytochrome P450 2C8Homo sapiens (human)0.151
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)1.1
Serine/threonine-protein kinase B-rafHomo sapiens (human)2
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)0.008
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.281
Cytochrome P450 2C19Homo sapiens (human)0.151
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)0.0073
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.9742
Ephrin type-B receptor 4Homo sapiens (human)1
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.001
Transcription factor p65Homo sapiens (human)0.055
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.086
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.29

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Althaus, IW; Amato, DM; Bridges, AJ; Denny, WA; Elliott, WL; Ellis, PA; Fry, DW; Gonzales, AJ; Han, HK; Harvey, PJ; Klutchko, SR; Meade, MA; Nelson, JM; Pace, G; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Tran, TP; Winters, RT; Zhou, H1
Russu, WA; Shallal, HM1
Althaus, IW; Black, SL; Blaser, A; Bridges, A; Denny, WA; Ellis, PA; Ellis, T; Fakhoury, S; Gonzales, AJ; Harvey, PJ; Hook, K; Lee, H; McCarthy, FO; Palmer, BD; Reed, JE; Rivault, F; Schlosser, K; Sexton, K; Smaill, JB; Spicer, JA; Tecle, H; Thompson, AM; Trachet, E; Winters, RT; Zhu, T1

Other Studies

3 other study(ies) available for canertinib dihydrochloride and gefitinib

ArticleYear
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Journal of medicinal chemistry, 2006, Feb-23, Volume: 49, Issue:4

    Topics: Alkynes; Amides; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line; Dogs; ErbB Receptors; Haplorhini; Humans; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Pyrimidines; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2006
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
    Journal of medicinal chemistry, 2016, 09-08, Volume: 59, Issue:17

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Dogs; ErbB Receptors; Heterografts; Humans; Injections, Intravenous; Macaca fascicularis; Male; Mice, Nude; Morpholines; Neoplasm Transplantation; Phosphorylation; Pyridines; Pyrimidines; Quinazolines; Quinazolinones; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship

2016